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Abbreviations:  
  
NMDA N-methyl-Daspartate  receptor 
CNS central nervous system 
BK bradykinin 
PGs prostaglandis 
5-HT serotonin  
PKC protein kinase C  
NO nitric oxide  
CWT cold withdrawal time 
PCR Polymerase Chain Reaction 
APS adenosine 5’ phosphosulfate 
PNS peripheral nervous system 
ALL dynamic mechanical allodynia 
WDT warm detection threshold 
CDT  cold detection threshold 
CPT cold pain threshold 
WDT warm detection threshold 
PHS paradoxical heat sensation 
MDT  mechanical detection threshold 
MPT  mechanical pain threshold 
TSL thermal sensory limen 
CPT cold pain threshold 
PHS paradoxical heat sensation 
PPT pressure pain threshold 
VDT vibration detection threshold 
CRPS complex regional pain syndrome 
PHN post-herpetic neuralgia 
NE norcpinephrinc 
COMT catechol-O-methyltransferase 
CNS central nerve system 
SNP single nucleatide polymorphism 
PI(3)K phosphatidylinositol-3-kinase  
TRP transient receptor potential  channel 
  
DRG dosal root ganglion 
TG trigeminal ganglion 
NG nodose ganglian 
mGluRs metabotropic glutamate receptors 
MAPK mitogen-activated protein kinase pathway  
NGF nerve growth factor  
PSQ Pyrosequencing 
GABA gamma-aminobuytric acid 
OPRM µ-opioid receptor 
TrkA receptor tyrosine kinases 
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1. INTRODUCTION 
1.1  Neuropathic pain overview  
1.1.1  Definition of neuropathic pain 
According to the International Association for the Study of Pain (IASP), neuropathic 
pain is defined as pain caused by damage of the neural structures that disrupts the 
ability of the sensory nerves to transmit correct information to the brain. Therefore, 
neurogenic pain syndromes arise as consequence of central and peripheral nerve 
damage, which generally characterized by three different properties [1]  
(a) it is often experienced in parts of the body that otherwise appear normal,  
(b) it is generally chronic, severe and resistant to over-the-counter analgesics,  
(c) it is further aggravated by allodynia (touch-evoked pain).  
 
1.1.2  Etiology of neuropathic pain  
Neuropathic pain may result from various causes that affect the brain, spinal cord and 
peripheral nerve system, including cervical or lumbar radiculopathy, diabetic 
neuropathy, cancer-related neuropathic pain, HIV-related neuropathy, spinal cord 
injury, trigeminal neuralgia, complex regional pain syndrome type (CRPS) II and 
post-herpetic neuralgia (PHN) [2,3]. Based on the location of the nervous system 
lesion, neuropathic pain syndromes may be divided into two groups, central and 
peripheral. Alterations of central nervous system physiology may play a significant 
role in many of the neuropathic pain conditions associated with peripheral pathology, 
making the distinction between peripheral and central pain less distinct than once 
believed. PHN is a typical example of neuropathic pain with mixed central and 
peripheral components [3]. Neuropathic pain, in contrast to nociceptive pain (i.e. 
post–operative pain), is described as "burning", "electric", "tingling", and "shooting" in 
nature. It can be continuous or paroxysmal in presentation. Neuropathic pain brings 
tremendous direct and indirect costs to patients and their families in terms of pain and 
suffering, health care expenditures as well as the quality of life.  
The hallmarks of neuropathic pain are chronic allodynia and hyperalgesia. Allodynia is 
defined as pain resulting from a stimulus that ordinarily does not elicit a painful 
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response (i.e. light touch). Hyperalgesia is defined as an increased sensitivity to a 
normally painful stimulus [4]. Primary hyperalgesia, caused by sensitization of 
C–fibers, occurs immediately within the area of the injury. Secondary hyperalgesia, 
caused by sensitization of dorsal horn neurons, occurs in the undamaged area 
surrounding the injury. However, clinically, both negative and positive signs may be 
present on examination. Negative signs are evidence of nerve damage such as 
sensory deficits, weakness, and reflex changes. Positive signs, also indicative of 
nerve damage, include hyperalgesia and allodynia. However, the epidemiology of 
neuropathic pain has not been adequately studied, partly because of the diversity of 
the associated conditions. Demonstrating a lesion of the nervous system compatible 
with particular symptoms and signs could provide strong support for considering the 
pain to be neuropathic. 
 
1.1.3  Mechanisms of neuropathic pain 
With the development of various experimental models of nerve injury, it has become 
increasingly clear that both peripheral and central mechanisms could be relevant to 
the pathogenesis of neuropathic pain (Figure 1a). Initially, injury or disease affecting 
peripheral nerves induces axonopathy and demyelization in injured afferents and 
perhaps also in uninjured neighbours, leading to a phenomena termed membrane 
remodelling which consequently increases neuronal excitability, and greatly contribute 
to the formation of peripheral sensitization. This is due in a large part to 
subtype-selective abnormalities in the expression and trafficking of Na+ channels and 
perhaps also to altered kinetic properties of unitary channels. The resulting excess 
discharge constitutes a primary neuropathic pain signal [5, 6].  
Recently, there has been increasing evidence that hypersensitivity and pain that 
occurring under various pathological conditions is often due to up-regulated 
expression and /or increased sensitivity of transient receptor potential (TRP) channels. 
Several lines of evidence point to the involvement of members of TRPV (vanilloid 
receptor) family in the aetiology of neuropathic pain [7].  
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Sustained painful stimuli result in central sensitization, which is defined as 
heightened sensitivity of spinal neurons, reduced activation thresholds and 
enhanced responsiveness to synaptic inputs. Under neuropathy status, sustained 
ectopic discharge can maintain central sensitization indefinitely and with it “Aβ pain 
“and tactile allodynia. At present, it is widely accepted that central sensitization is 
largely mediated by the glutamatergic N-methyl-D-aspartate (NMDA) receptor 
(Figure 1b). In addition, some evidence has been demonstrated that the 
sympathetic nervous system also plays an important role in neuropathic pain by 
analgesia following sympathectomy in animals and humans [8, 9]. Furthermore, 
several lines of evidence indicated that immune cells, such as endoneurotrophilis 
and macrophages, might be involved in the initiation of neuropathic pain and its 
maintenance [10, 11]. 
 
1.1.4  Therapy of neuropathic pain   
The pharmacotherapy is currently the mainstay of treatment in patients with 
neuropathic pain. Since hyperexcitability is associated with abnormal sodium channel 
regulation in neuropathic pain, alternative treatment strategies have targeted activity 
against specific cellular components involved in the pain-processing loop, either by 
blocking Na+, Ca2+ and K+ channels as to suppress neuronal excitability at the level of 
the spinal cord or by potentiating the effects of the various antinociceptive substances 
released via the central descending systems [12].  
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Figure 1: (a) Tissue trauma or nerve injury leads to the release of inflammatory mediators as 
well as increased neuronal excitability at the site of injury, resulting in a reduction in the pain 
threshold at the site (peripheral hyperalgesia). Central sensitization is an increase in the 
excitability of spinal neurons as a result of persistent exposure to afferent input from 
peripheral neurons, CNS = central nervous system, BK = bradykinin, PGs = prostaglandins 
and 5-HT = serotonin  
(b) Schematic representation of the activation of NMDA receptor in relation to pain. The 
activation of NMDA in response to the released glutamine results in the removal of Mg2+ which 
leads to the ca2+ influx; ca2+ ions flowing into cell activates the protein kinase C (PKC), an 
enzyme required for the synthetics of NO, followed by the activation of substance P that binds 
to the NK-1 receptor triggering c-fos gene expression and hypersensitivity.  
 
A wide variety of drugs, such as 5% lidocaine patches, nonsteroidal anti-inflammatory  
drugs (NSAIDs), anticonvulsants (e.g. carbamazepine, gabapentin, lamotrigine), and 
tricyclic antidepressants (TCAs), e.g. amitriptyline hydrochloride, desipramine 
hydrochloride), could  be used as first-line therapy in the treatment of neuropathic 
pain. The second-line drug, which mainly encompasses narcotics analgesics or 
NMDA receptor antagonist, could be applied to patients who do not respond to 
treatment with first line agents. The choice of medication should be directed toward 
the type of painful symptom described. Patients who do not respond to monotherapy 
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with any of the first- or second-line agents may respond to combination therapy or 
may be candidates for invasive therapy in pain clinic [13, 14].  
Nowadays, pain research is directing on new molecular methods, such as gene 
therapy, stem cell therapy and viral vectors for delivery of biologic antinociceptive 
molecules. These methods could provide a new therapeutic approach to neuropathic 
pain relief. Pharmacological treatment for the symptoms of painful neuropathy, 
however, is still considered to be difficult, as the treatment effect is frequently variable 
between individuals. Traditionally, this variation has been explained by variable 
bioavailability, differences in intensities of pain stimuli and individual differences in 
pain perception. Recently, there is increasing evidence supporting that 
polymorphisms in some candidate genes may affect the expression and function in 
target product, leading to variability in pain perception or dose requirement of drugs 
used for pain treatment [15,16]. 
 
1.2  TRP channels and pain 
Transient receptor potential (TRP) channels have been found in many cell types. 
Three TRP channels including TRPV1, TRPM8 and TRPA1, which have been shown 
to be expressed in primary afferent nociceptors, are gradually emerging as sensory 
transducers that may participate in the generation of pain sensations evoked by 
chemical, thermal and mechanical stimuli (as shown in Figure 2). 
 
1.2.1  TRPV1 
Since the molecular identification of the capsaicin receptor, now known as TRPV1, 
transient receptor potential (TRP) channels have occupied an important place in the 
understanding of sensory nerve function in the context of pain. Functional TRPV1 is 
expressed both in different level of neuron tissues like brain, dorsal root ganglion 
(DRG), trigeminal ganglion (TG), nodose ganglian (NG) neurons and in non-neuronal 
tissues which include gastric epithelial cells, airway epithelial cells, liver, vascular 
endothelium, mast cells and bladder. The increase in TRPV1 expression was 
suggested to contribute to the pathogenesis of various disease states, such as 
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multiple types of pain, vulvar allodynia as well as inflammatory bowel disease, 
pancreatitis and migraine [17, 18]. TRPV1 function has also been investigated in 
models of neuropathic pain. Several lines  
 
Figure2. Selected stimuli and intracellular pathways that contribute to the sensitization of TRP 
function in terminal primary sensory neurons. Besides activation by endogenous activating 
lipids via PLC and PLA pathways, the TRPV1 receptor can be activated by heat (>43 °C), acid 
and pungent vanilloid compounds. In contrast to the TRPV1 receptor, The TRPM8 receptor 
can be activated by many cooling compounds (23 °C-26 °C) and odorants like menthol. In 
addition, the TRPA1 receptor can be activated by endogenous inflammatory mediators and by 
diverse exogenous irritants, including mustard oil, garlic and allicin. Probably, TRPA1 is 
functionally coupled to TRPV1 and regulated by similar PLC-dependent sensitization 
pathways. However, whether the TRPA1 receptor respond to mechanical stimuli is 
unidentified. BK = bradykinin, PGs = prostaglandins and 5-HT = serotonin, PLA/PLC pathway 
= phospholipase A / phospholipase C, PGE2 = Prostaglandin E2, AA = arachidonic acid, 
GPCR = G-protein-coupled receptor, 5HT-2A = serotonin receptor.   
 
 
of evidence point to the involvement of members of the TRPV family, especially 
TRPV1 in the aetiology of neuropathic pain [19]. It can be speculated that 
up-regulated expression of TRPV1 in myelinated fibers (A-neurons) is part of the 
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neuropathic pain phenotypic switch and contributes to hyperalgesia. TRPV1 also 
plays an important role in chemical and thermal hyperalgesia in a model of diabetic 
neuropathy. The application of Trpv1-specific siRNA VsiR1 for rats with neuropathic 
pain showed that the Trpv1-specific siRNA VsiR1 diminishes the frequency of 
cold-induced paw lifting by approximately 50%, indicating a reduction of cold allodynia 
[18]. More interestingly, animal experiment showed this receptor may have a 
protective role in the development of mechanical hyperalgesia [20]. 
The TRPV1 channel is encoded by the TRPV1 gene, located on chromosome 
17p13.3. Several exonic TRPV1 polymorphisms in coding region have identified 
recently, including the two common single nucleotide polymorphism (SNP) rs222747 
and rs8065080, also known as TRPV1 Met315lle and IIe585Val, which substitutes 
methionine to isoleucine at codon 315 and isoleucine to valine at codon 585, 
respectively. To date, there have been few studies in the literature reporting the 
association between genomic variations of the TRPV1 and the pain perception or the 
development of the pathologic pain in humans. An in vitro study by Kayes et al [21] 
failed to confirm that the IIe585Val substitution alters the receptor function. Another 
study by Kim et al, however, suggested that this substitution at codon 585 significantly 
influences the cold withdrawal time (CWT) in Caucasian females [20]. Haplotypes 
analysis including these two polymorphisms were recently identified by Kim et al  in a 
European Americans, but there was no significant association between short duration 
cold pain sensitivity and variations in TRPV1 in a gender dependent manner [22]. Until 
now, the detailed mechanism explaining how these SNPs influence the mRNA 
expression and their relevant function in vivo is unclear. In addition, it remains open 
whether these polymorphisms in human could influence pain perception on the 
condition of neuropathic pain. Hence, further investigation to explore these 
associations between polymorphism and pain perception is necessary.  
 
1.2.2  TRPM8 
The TRPM8 channel is encoded by TRPM8, which is located on the chromosome 
2q37.1. TRPM8 is expressed in prostate and in small-diameter trigeminal and dorsal 
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root ganglion (DRG) neurons, suggesting its specific expression in C-and possibly 
A-fibers, where TRPM8 functions as cold sensing pain pathway and sensor [20, 23]. 
TRPM8, also known as the menthol receptor, can be activated by many cooling 
compounds and odorants, which are dependent on different factors such as intra and 
extracellular Ca2+ concentration and PH [19, 20]. It has been previously proposed that 
TRPM8 is a candidate as sensory transducer contributing to pain hypersensitivity due 
to its property of responding to both innocuous and noxious temperature. Recently, it 
has been shown that ethanol is capable of inhibiting this channel as one of known 
TRPM8 modulators, but the exact mechanism how the ethanol affect or modulate the 
activity of TRPM8 channel is still poorly understood. 
More interestingly, it has been demonstrated that activation of TRPM8 in sensory 
afferents of neuropathic pain rat models by either cutaneous or intrathecal application 
of pharmacological agent or modest cooling causes inhibition of sensitized pain 
response, thereby inhibiting the characteristic sensitization of dorsal-horn neurons 
and behavioural-reflex facilitation. The mechanism of analgesic effect in TRPM8 
activation could be due to the central mediation and possibly relies on group II/III 
metabotropic glutamate receptors (mGluRs), which very likely respond to glutamate 
released form TRPM8-containing neurons to suppress nociceptive inputs [24]. 
There is increasing evidence that mutation in coding regions could alter the function of 
the TRPM8 channel. Colburn et al showed that sensory neurons derived from trpm8 
null mice lack detectable levels of TRPM8 mRNA and protein and that the number of 
these neurons responding to cold (18°C) and menthol (100 mM) is greatly decreased. 
Furthermore, compared with WT mice, null mice display deficiencies in certain 
behaviours; these results suggest that TRPM8 may play an important role in certain 
types of cold-induced pain [25]. However, in a study in humans, Kim et al could not 
find any association between TRPM8 and cold or heat pain sensitivity and speculated 
that TRPM8 receptor was possibly not activated by cold temperature (2-4°C) used 
[22].  
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1.2.3  TRPA1 
The TRPA1 protein encoded by the TRPA1 gene, is located on the chromosome 8q13. 
As a member of the TRP family of ion channels, TRPA1 is mainly expressed in the 
inner ear, trigeminal and DRG neurons, where there have been proposed roles in 
sensing sound, painful cold, and irritating chemicals [19].  
Traditionally, the TRPA1 was proposed as a candidate for the hair-cell transduction 
channel, but Kwan and colleagues found that TRPA1 seems to be unnecessary for 
hair-cell transduction [26]. The observation of trpa1−/−(lacking trpa1) mice revealed 
that neither hearing behaviour nor transduction currents changed in response to 
bundle deflections, further confirming the possibility that another TRP channel can 
compensate the loss of TRPA1. 
The majority of studies point to an important role for TRPA1 in the pain response to 
endogenous inflammatory mediators and to diverse exogenous irritants, including 
mustard oil, garlic, wintergreen oil, clove oil, ginger and cinnamon oil, all of which elicit 
acute painful burning or pricking sensation [20]. Some behavioural studies in mice 
lacking trpa1 confirmed these effects in nociception. More interestingly, being 
consistent with a role in nociception, TRPA1 is highly co-expressed with TRPV1 in 
small-diameter peptidergic nociceptors while it is rarely co-expressed with TRPM8. 
TRPA1 has also been linked to cold hyperalgesia in the condition of neuropathic pain. 
Both inflammation and nerve injury increase the expression of TRPA1 in DRG 
neurons. Such over-expression, which appeared to be driven by nerve growth factor 
(NGF)-engaging the p38mitogen-activated protein kinase pathway (MAPK), 
contributes to injury-induced cold hyperalgesia because trpa1 knock down by siRNA 
strategies suppressed cold hyperalgesia in a rat nerve injury model. Obata et al  
further confirmed that NGF-induced TRPA1 increase in sensory neurons via p38 
activation is necessary for cold hyperalgesia [27]. Therefore, blocking TRPA1 in 
sensory neurons might provide a fruitful strategy for treating cold hyperalgesia caused 
by inflammation and nerve damage.   
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From some animal experiments, it has been obviously shown that mice trpa1 gene 
knock out or trpa1 antagonist exhibited behavioural change in response to the pain 
stimuli, which illustrated the important role of TRPA1 in pain perception. Genomic 
variations may alter protein expression or possibly have significant consequences on 
the function of the protein. Up to date, there have been few data suggesting that 
polymorphism in the trpa1 gene might contribute to the interindividual variation in pain 
perception. For example, in the study by Kim et al [22], it could be demonstrated that 
homozygote carriers of the intronic TRPA1 G38218A variant (rs1198795) have less 
pain tolerance to the cold stimuli compared to homozygote G carriers. But detailed 
knowledge of regulation is less available. Hence, more research work intended to 
clarify clinical impact of these genetic variations is required. 
 
1.3  Aim of the study 
Candidate gene studies on the basis of biological hypotheses have been a practical 
approach to identify relevant genetic variation in complex traits. There is growing 
evidence showing that single nucleotide polymorphisms (SNPs) in candidate genes, 
including TRPV1, TRPA1 and TRPM8, may influence pain sensitivity in animal 
models of neuropathic pain. However, the exact role of these SNPs in pain perception, 
interpretation and behavioural expression in humans are currently unknown. As we 
know, the research for predictive SNPs within genes may require the examination not 
only of the exons, but also of the promoters and/or the area of intron-exons 
boundaries and mRNA processing signals. Therefore, in this study, two SNPs were 
selected from TRPV1, 3 SNPs from TRPA1 and 6 SNPs from TRPM8. The SNPs 
were located in exonic and promoter regions and were examined for their frequency in 
a large sample of patients with different neuropathic pain entities and healthy controls. 
They were further investigated for their effects on pain sensitivity.  
 
2  MATERIALS AND METHODS 
2.1  Patients  
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The study was carried out in cooperation with the German Research Network on 
Neuropathic Pain headed by Prof. Dr. Ralf Baron, Division of Neurologic Pain 
Research, Department of Neurology at the University Hospital Schleswig-Holstein 
Campus Kiel and Prof. Dr. Dr. Thomas Toelle, Department of Neurology at University 
Medical Centre Rechts der Isar of the Technical University Munich. The study was 
performed in accordance to the principles of the Helsinki declaration. All patients gave 
their written informed consent and the ethics committee of the medical faculty of the 
University of Kiel and the local ethics committees of the participating centres 
approved the study. We analyzed the neuropathic pain patient population in a primary 
study. All patients were Caucasians and unrelated to each other. So, a total of 296 
patients were recruited to the current study for genotyping. Due to the failed collection 
of clinical data in some cases, there were 236 patients with a mean age of 57.4 years 
(140 women, 96 men) investigated by further statistic analysis (Tab. 1). 
 
Table 1: Demographic data of 236 neuropathic pain patients  
 
Subgroup number (male/female) Age (years) 
Central pain 9/8 51.1 ± 11.7 
Ccomplex regional pain syndrome 9/47 51.1 ± 13.3 
Peripheral nerve injury 13/14 52.6 ± 15.3 
Post-herpetic neuralgia 5/22 52.2 ± 16.7 
Polyneuropathy 42/29 67.4 ± 12.0 
Trigeminal pain 13/17 60.9 ± 12.7 
Other neuropathy  5/2 56.5 ± 15.7 
Data expressed as the number of patients, mean ± SD 
 
2.2  Volunteers 
For comparison of the genotype distribution, 252 healthy volunteers were enrolled at 
the Institute of Pharmacology of the Kiel University under a clinical protocol approved 
by ethics committee of the medical faculty of the University of Kiel. All volunteers gave 
their written informed consent and were German Caucasians.  
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2.3  Experimental pain test measurements   
In each participating centre, all 13 QST procedures were performed by trained 
observers using the same equipment and standardized instructions to the patients. All 
test techniques are based on the quantitative sensory testing of the German 
Research Network on Neuropathic Pain (DFNS) [28, 29].  
 
2.3.1  Thermal detection, thermal pain thresholds and paradoxical heat 
sensation 
The thermal test includes CDT (cold detection threshold), WDT (warm detection 
threshold) , PHS (paradoxical heat sensation), TSL (thermal sensitivity limen) and 
CPT (cold pain threshold). Cold and warm detection thresholds were firstly measured. 
In addition, patients were asked about paradoxical heat sensations (PHS) during the 
thermal sensory limen (TSL) procedure of alternating three times of warm and cold 
stimuli. Then cold pain and heat pain thresholds were determined (CPT, HPT).  
 
2.3.2  Mechanical detection threshold for modified von Frey filaments 
The mechanical detection threshold (MDT) was measured with a standardized set of 
modified von Frey hairs that exert forces upon bending between 0.25 and 512 mN. 
Five threshold determinations were made by using the “methods of limits”, the final 
threshold was the geometric mean of these five series. Similarly, the mechanical pain 
threshold (MPT) was measured using custom-made weighted pinprick stimuli as a set 
of seven pinprick mechanical stimulators, which usually were applied at a rate of 2 s 
on, 2 s off in an ascending order until the fist percept of sharpness was reached. 
 
2.3.3  Mechanical pain threshold for pinprick stimuli and dynamic mechanical 
allodynia 
Mechanical pain sensitivity (MPS) was assessed using the same set of pinprick 
stimuli to obtain a stimulus-response function for pinprick-evoked pain. Patients were 
asked to give a pain rating for each stimulus on a “0-100” numerical rating scale. 
Furthermore, dynamic mechanical allodynia (ALL) was assessed as part of the test 
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above, using a set of three light tactile stimulators (cotton wisp, cotton wool and brush) 
as moving innocuous stimuli.  
 
2.3.4.  Windup ratio-temporal pain summation for repetitive pinprick stimuli 
In this test, after a single pinprick stimulus and a series of 10 repetitive pinprick stimuli 
of the same physical intensity separately applied to the patients, patients were asked 
to give a pain rating representing the single stimuli, and the estimated mean over the 
whole series of 10 stimuli using a “0-100” numerical rating scale. Wind-up ration 
(WUR) was calculated as the ratio: mean rating of the five series divided by the mean 
rating of the five single stimuli.  
 
2.3.5  Vibration detection threshold and pressure pain threshold  
The vibration detection threshold (VDT) was recorded at a time point when patients 
could not feel the vibration of tuning fork placed over a bony prominence. VDT was 
determined as a disappearance threshold with three stimulus repetitions. In addition, 
the Pressure pain threshold (PPT) was measured by using a pressure gauge device. 
The PPT was determined with three series of ascending stimulus intensities, each 
applied as a slowly increasing ramp of 50 kPa/s (~5 kg/cm2 s). 
 
2.3.6  Test side and control side 
This test stimuli were applied in runs alternating between the affected test side and a 
contralateral non-afftected control site. 
 
2.3.7  Data evaluation 
In order to describe which measure is more sensitive to detect sensory plus and 
minus signs, the absolute reference data were used to normalize test results of 
individual patients by calculating the z-transform: Z=(valuepatient–meancontrols)/SDcontrols. 
Subjects were blinded with regard to the temperature of the stimulus.  
 
2.4  Genotyping  
 - 14 - 
To study possible association between neuropathic pain and single nucleotide       
polymorphism (SNP) in candidate genes (Table1), a total of 11 single nucleotide 
polymorphism in 296 patients and in 253 volunteers was genotyped by PSQ, 
respectively. Besides volunteers, prepared DNA was obtained from Department of 
Neurology of the Munich University Medical Centre and all DNA sample stored at -4 
°C until PCR reactions were performed. Primer and pyrosequencing primer were 
designed by PSQ assay design software (Biotage, Uppsala, Sweden) 
 
2.4.1  Polymerase Chain Reaction (PCR) 
DNA fragment containing polymorphic sites were amplified from genomic DNA using 
specific primers (as showed in Tab. 2), which were designed by pyrosequencing PSQ 
assay design software (Biotage, Uppsala, Sweden). DNA amplifications for these 
SNPs were typically performed under similar conditions for each reaction with 1µl of 
genomic DNA, 0.2 µM of forward and reverse primers (TIB Molbiol, Berlin, Germany), 
2.5 µM magnesium chloride, 1.0 µM dNTPs (Biotage) and 0.15 µl of Taq DNA 
polymerase (Invitrogen, Karlsruhe, Germany) , in a total volume of 25 µl (Tab. 3). PCR 
was performed under the following conditions: initial denaturation for 4 min at 94 °C, 
followed by 50 cycles at 94 °C for 30 s, annealing at 63 °C (61 °C for SNP rs13268757) 
for 30s and at 72 °C for 30 s, and 7 min at 72 °C (Tab. 4). All PCR amplifications were 
carried out using a GeneAmp 9700 thermocycler (Applied Biosystems, Darmstadt, 
Germany). For controlling the PCR reaction, the DNA fragments were separated on a 
2.0% agarose gel (AppliChem, Darmstadt, Germany) and visualized after ethidium 
bromide staining by a digital image station (Kodak, Stuttgart, Germany).  
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Table 2: Primers used for genotyping of polymorphisms in three TRP genes 
 
Gene SNP ID mRNA 
location 
Primer 
name 
Primer sequence 
TRPV1 rs222747 G1103C TRPV1-1 F:5'ACG AAG TTT GTG ACG AGC ATG TA 
    R:5'Bio-TCC CTT CTT GTT GGT GAG CT 
    S:5'-ATG TAC AAT GAG ATT CTG AT 
 rs8065080 A1911G TRPV1-2 F:5'-Bio-GCG CTG ACC AAG CTC ATT ACC T 
    R:5'-TGG CCT CGG CTC TGA TGA 
    S:5'-CCG TTT  CAT GTT TGT CTA 
TRPM8 rs17862932 C2235T TRPM8-4 F:5'-GGG TCC AGG AAG AAA CCT GTC 
    R:5'-Bio-GCG ATC TAG AAG ACC ACA TTC C 
    S:5'-GTA CTA TGTTGT GGT GTT CTT 
 rs7593557 G1296A TRPM8-3 F:5'-Bio-GAG TCT TTT CCT GCC CTC 
    R:5'-CGG TCA TTG GTG AAA ATC TCA T 
    S:5'-CAG TTA TCC TTG TCT TGC 
     
 rs13004520 G780C F:5'-TTT AGC CCA GTA CCT TAT GGA TG 
 rs28901637 
rs11562975  
A787T 
G790C  
TRPM8-1 
R:5'-Bio-CTA GCT GAT TCC GGA GCT TTG 
 rs17868387 A792G  S:5'-TTA TGG ATG ACT TCA CAA 
     
TRPA1 rs13268757 C182T TRPA1-1 F:5'-Bio-CTC CAG GGC GCC ACA TCT 
    R:5'-TTT CGC TGC CTG TGA GCT G 
    S:5'-GGT GGG GTC AAT GAA 
 rs920829 G710A TRPA1-2 F:5'-TGA TCA TTG CGT GCA CCA C 
    R:5'-Bio-TCC TCT TAA GCG GGG AGT ACA TAC 
    S:5'-CGT GCA CCA CAA ATA AT 
 rs959976 A3228G TRPA1-3 F:5'-Bio-TTG TCT TAT TTC CCC AGT GCA A 
    R:5'-TGG CAC ATG CTT AAG AAA AAG TTC 
    S:5'-ATT TTT TAT CCG ACA GC 
Abbreviations: F, forward primer; R, reverse primer; S, sequencing primer; dNTP, deoxynucleotide triphosphates; 
Dispensing order: sequence order given by Pyrosequencing software according to each analyzed template 
sequence.  
 
Formatierte Tabelle
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Table 3:  PCR reaction reagents used for amplification of SNPs in three TRP genes. 
 
Reagent Volume [µl] Concentration 
Taq-buffer (10x) 2.5 1 x 
MgCl2 (50 mM) 1.25 2.5 mM 
dNTPs (10 mM) 2.5 1 mM 
Primer forward (10 mM) 0.5 200 nM 
Primer reverse (10 mM) 0.5 200 nM 
Taq-DNA-polymerase 
(5U/µl) 
0.15 0.03 U/µl 
DNA (30-100 ng/µl) 1.0  
H2O 16.9  
Total volume 25.0  
 
Table 4:  Thermocycler conditions of PCR-reaction used for amplification of SNPs in 
three TRP genes. 
 
Denaturation Denaturation Annealing Elongation Terminal 
elongation 
4 min 30 s 30 s 30 s 7 min 
94 °C 94 °C 63 °C* 72 °C 72 °C 
 45 cycles  
  *  61 °C for SNP rs13268757   
 
2.4.2  Pyrosequencing (PSQ) 
10 µl of PCR-reaction product were aliquoted in each well with 30 µl of pure water 
(Biochrom AG; Berlin, Germany) and 37 µl of binding buffer (Biotage) as well as 3µl 
streptavidine-coated sepharose beads (GE Healthcare Bio-Sciences, Uppsala, 
Sweden), the mixture were incubated in a shaker for 20 min. Afterwards using the 
Vacuum Prep workstation, biotinylated single-stranded PCR fragments were treated 
with 70% ethanol (Merck, Darmstadt, Germany), 0.1%mol/l NaOH and washing buffer 
(Biotage),and transferred to 96-well plates, containing annealing buffer and 10 pmol of 
sequencing primer in a total volume of 12 µl each. Hybridization was applied by 
incubation at 80 °C for 2 min, the plate was cooled to room temperature.  
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According to the volume information, the enzymes, which include DNA polymerase, 
ATP sulfurylase, luciferase and apyrase, the substrates including adenosine 5’ 
phosphosulfate (APS) and luciferin, as well as the nucleotides were filled in the tips 
stored in a dispensing tip holder, from where they were added automatically into each 
well of the 96 wells plate containing the sequencing primer /PCR product mix.  
The pyrosequencing technique is based on the detection of pyrophosphate released 
during polymerization of DNA as illustrated in Figure 3. 
 
 
 
 
 
 
 
 
Figure 3a: Step 1. A polymerase catalyzes incorporation of nucleotide acid chain. As result of 
the incorporation, a pyrophosphate molecule (ppi) is released and subsequently converted to 
ATP by ATP sulfurylase.  
 
 
 
 
 
 
 
 
 
Figure 3b: Step 2. Meanwhile, light is produced in the luciferin reaction during which a 
luciferin molecule is oxidized. The light is proportional to the amount of incorporated 
nucleotide and seen as a peak in the program   
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Figure 3: Step 3. The excess of the added nucleotide wil be degraded by apyrase, the 
produced ATP also will rapidly be degraded by apyrase. 
 
 
 
 
 
 
 
 
 
Figure 3c: Step 4. Pyrosequencing raw data obtained as pyrogramme, in which proportional 
peak signals represent one or two base incorporations. Nucleotide addition, according to the 
dispending order, is indicated below the program and the obtained sequence in indicated 
above the program.  
 
2.5  Statistical analysis  
Descriptive data are presented as mean±SD. The Kruskal-Wallis test and the 
Jonckheere-Terpstra test were performed to test the association between SNPs and 
13 pain test parameters, using computer software SPSS (version 11.5). A 
Kruskal-Wallis test was used to determine whether continuously measured QST 
parameters differed according to variants location, and to determine the association 
between the candidate SNPs and the QST parameters. The Jonckheere-Terpstra test 
was used to assess the statistical significance of the trend in continuously measured 
 - 19 - 
QST parameters across genotypes. In addition, Mann-Whitney U-test (multiple 
comparison) was used to compare the difference dependent on genotype either on 
test side or on control side.  To exam the equality of the allele and genotype 
frequencies between the patients and controls, Statcalc (version 6) was used for 
calculation of odds ratios. Haplotype analysis was performed using the SHEsis 
software, which provided free service from online. A P-value below 0.05 was 
considered to be statistical significant and calculated as two-sided significance.  
 
3.  RESULTS 
 
3.1.  The characteristics of seven subgroups of neuropathic pain  
Mean values of all quantitative sensory testing (QST) parameters of test and control 
sides are shown in Figure 4. These QST parameters were objectively designed to 
detect pain patterns after partial nerve lesion, which is indirectly consistent with the 
characteristics of different afferent nerve fibers (nociceptive C-fibers and 
non-nociceptive myelinated A-fibers). Theoretically, cutaneous sensitivity is mediated 
by various populations of Aβ, Aδ, and C-fiber afferents. Brush and touch by a blunt 
von Frey type probe predominately activate Aβ-fiber low–threshold mechanoreceptors. 
Gently cooling the skin activates Aδ-fiber thermoreceptors. Contact with sharp objects 
such as pinpricks predominantly activates Aδ-fiber nociceptors. Gently warming the 
skin activates C-fiber thermoreceptors. Painful heat stimuli activate both Aδ and 
C-fiber nociceptors, but due to their lower thresholds only C-fibers are involved in heat 
pain threshold. Therefore, based on the quantitative sensory testing (QST), the 
Aβ-fiber can be represented by VDT and MDT, whereas the C-fiber function is 
represented by the WDT and HPT. The presence of abnormal cold pain threshold 
(CPT) indicates a disturbance of Aδ-cold sensation.  
The normal range from plus 2 to minus 2 in patients profile was presented by grey 
zone. The minus z-score represents loss of sensory function, those minus z-score 
outside of normal range shows significant loss of sensory function such as 
hypoesthesia. In contrast, the plus mean z-score above normal range represents the 
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gain of sensory function like hyperalgesia or allodynia. 
 
Figure 4:  Z- score sensory profiles of 235 patients on both test and control sides (test side 
represented the affected side of neuropathic pain, whereas the control side signified the 
non-affected side of neuropathic pain). These patients, who are being scattered among seven 
types of neuropathic pain, exhibited different response to 11 items of QST parameters applied. 
Since the majority of mean value of z-score was distributed within the normal range, the patients 
were subsequently divided into subgroups for further investigation. 
 
 
To further illustrate the characteristics of subgroups of neuropathic pain, patients were 
divided into seven subgroups, including central pain, complex regional pain 
syndrome(CRPS), peripheral nerve injury, polyneuropathy, trigeminal pain, post 
herpetic neuralgia and other neuropathy. The comparison data on both test and 
control side among subgroups are shown in Figures 5 a-g. Compared to the control 
side, central pain patients apparently exhibited hypoesthesia in CDT, WDT, TSL MDT 
and VDT on test side (Figure 5a). Similarly, hypoesthesia with regard to MDT and 
VDT was also observed in post herpetic neuralgia (PHN) (Figure 5e), polyneuropathy 
(Figure 5f) and peripheral nerve injury patients (Figure 5d), respectively. On the 
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contrary, the CRPS patients showed static hyperalgesia to blunt pressure (PPT) on 
the test side (Figure 5b). In the trigeminal pain (Figure 5g) and other neuropathy 
groups (Figure 5c), there is no obvious loss or gain of sensory function by comparing 
test and control side.  
 
Figure.5a. Pain patterns of test and control side in central pain patients. Compared to the control side, 
central pain patients apparently exhibit hypoesthesia to thermal stimuli (CDT, WDT, TSL) and VDT at 
test side. 
 
       
Figure 5b: Pain patterns of test and control side in complex regional pain syndrome (CPRS) patients. 
QST-profile of test side shows static hyperalgesia to blunt pressure (PPT). There was neither allodynia 
nor hyperalgesia on the control side.  
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Figure 5c: Pain patterns of test and control side in other neuropathy subgroup. Neither hypralgesia nor 
alodynia was observed on test side and control site. 
 
 
 
 
 
Figure 5d: Pain patterns of test and control side in peripheral nerve injury patient. QST-profile of the 
test side referred to the affected side confirms hypoesthesia in vibration detection threshold (VDT). 
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Figure 5e. Pain patterns of test and control side in post-herpetic neuralgia (PHN) patient, Comparing 
the control side, the mechanical detection threshold (MDT) of test side decreased dramatically, 
exhibiting tactile hypoesthesia.  
 
 
 
Figure 5f: Pain patterns of test and control side in polyneuropathy patients. QST-profile of test side 
compared to the control side suggests tactile hypoesthesia (MDT) and hypoesthesia in vibration 
detection threshold (VDT), even though the pattern of control side is more close and similar to the test 
side.  
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Figure 5g: Pain patterns of test and control side in trigeminal pain patients. QST-profile of the control 
side versus test side shows no significant difference. 
 
3.2.  The distribution of genetic polymorphisms 
The genotype distribution of all investigated polymorphisms showed no deviations 
from Hardy-Weinberg equilibrium neither in patients nor in controls. To evaluate 
whether the genotypes investigated may act itself as susceptibility factors for 
neuropathic pain, the genotype and allele frequencies were compared between the 
case group and healthy volunteers. For most genotypes and alleles, there was lack of 
evidence of an association, since there was no statistical difference (P>0.05). 
However, the G variant of the 1911A>G polymorphism in TRPV1 was more frequent 
in patients than in controls (42.8%) than in the controls group (36.0%, OR=1.28, 95% 
CI 1.00-1.65, P=0.04) (Table 5). 
In a second approach, the linkage disequilibrium (LD) between each pair in TRPV1 as 
well as TRPA1 was checked by using SHEsis software. Two polymorphisms (2235 
C>T and A787T) in TRPM 8 were not included into the haplotype calculation due to 
the low frequency. All the P-value corresponding to haplotypes are shown in Table 6. 
There was significant difference between patients and controls groups in the 
haplotype C-A consisting of TRPV1 1103 T>C and 1911A>G. The frequency of 
haplotype C-A was lower in patients (46.1%) than in controls 
(53.8%, ,OR=0.73,95%CI 0.57-0.94) (p=0.02). The global haplotype frequency, 
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however, showed no significant differences between patients and controls in TRPA1 
(χ2=6.44, P=0.09), TRPV1 (χ2=1.62, P=0.65) and TRPM8 (χ2=0.67, P=0.72). 
 
Tab. 5: Allele frequencies and frequencies of genotypes in 296 patients and in 253 
volunteers  
Gene Location 
SNP 
 Allele Allele Frequency (%) p-value Odds ratio Geno- 
type 
Frequency of 
genotype(%) 
p 
 mRNA Protein  Pat Controls d.f.=1 (95%)CI  Pat Controls d.f.=2 
TRPV1 G1103C Met315Ile C 75.0 72.8 0.4 1.122 CC 56.6 52.4 0.63 
   G 25.0 27.2  (0.85-1.48) CG 36.8 40.7  
        GG 6.6 6.9  
 A1911G Ile585Val A 63.2 57.2 0.04 1.285 AA 41.0 33.2 0.14 
   G 36.8 42.8  (1.00-1.65) AG 44.4 48  
        GG 14.6 18.8  
TRPM8  C2235T Thr762Ile C 100 99.8 0.93 - CC 100 99.6 0.93 
   T 0.0 0.2   CT 0.0 0.4  
        TT 0.0 0.0  
 G1296A Ser419Asn G 93.6 94.9 0.48 0.83 GG 87.5 91.1 0.43 
   A 6.4 5.1  (0.49-1.38) GA 12.2 7.6  
        AA 0.3 1.3  
 G780C Arg247Thr G 94.2 95.8 0.22 0.42 GG 88.3 92.4 0.05 
   C 5.8 4.2  (0.81-2.47) GC 11.7 6.8  
        CC 0.0 0.8  
 A787T Pro249Pro A 99.5 99.4 0.82 1.17 AA 99.0 98.8 0.82 
   T 0.5 0.6  (0.19-7.26) AT 1.0 1.2  
        TT 0.0 0.0  
 G790C Leu250Leu G 88.9 90.4 0.41 1.17 GG 77.7 81.2 0.31 
   C 11.1 9.6  (0.79-1.75) GC 22.3 18.4  
        CC 0.0 0.4  
 A792G Tyr251Cys A 94.3 95.6 0.35 0.77 AA 88.7 92 0.08 
   G 5.7 4.4  (0.44-1.38) GA 11.3 7.2  
        GG 0.0 0.8  
TRPA1 C182T Arg3Cys C 86.0 85.0 0.66 1.08 CC 70.1 72.3 0.54 
   T 14.0 15.0  (0.76-1.52) CT 29.9 27.3  
        TT 0.0 0.0  
 G710A Glu179Lys G 89.0 89.4 0.83 1.04 GG 79.7 80.4 0.98 
   A 11.0 10.6  (0.70-1.53) GA 18.6 18.0  
        AA 1.7 1.6  
 A3228G His1018Arg A 83.3 83.7 0.84 0.97 AA 70.0 69.1 0.36 
   G 16.7 16.3  (0.70-1.33) AG 26.6 29.3  
        GG 3.4 1.6  
P-value of genotype was calculated by using wild-type homozygotes vs. heterozygotes and variant homozygotes 
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Tab. 6:  Estimated haplotype frequencies in 296 patients and 253 controls  
 
TRPV1 G1103C  A1911G                 Frequency (%)  P-value    OR (95% CI)  Global result 
haplotype    Pat Control    
1 C A   53.6 46.1 0.02 1.35(1.06-1.73) χ2=6.44  
2 C G   21.4 26.7 0.05 0.75(0.56-1.00) df=3  
3 G A   9.6 11 0.44 0.85(0.57-1.28)    P=0.09 
4 G G   15.4 16.2 0.74 0.94(0.67-1.32) 
          
TRPA1   C182T  G710A  A3228G         Frequency (%)  P-value  OR (95% CI) 
haplotype    Pat Control    
1 C A A  0.4 1.3 -   - χ2=0.98  
2 C A G  10 9.2 0.67 1.10(0.72-1.66) df=3  
3 C G A  75 73.6 0.92 1.01(0.76-1.35)    P=0.81 
4 C G G  0.4 1.4 -   -  
5 T A A  0 0 -   -  
6 T A G  0 0 -   -  
7 T G A  9.1 7.7 0.38 0.82(0.53-1.27)  
8 T G G  5.9 5.4 0.74 1.09(0.64-1.85)  
          
TRPM8  G1296A G780C  G790C  A792G  Frequency (%)   P-value   OR (95% CI) 
haplotype         
1 G G G A 82.9 84.7 0.44 0.88(0.62-1.23) χ2=0.67 
2 G G C A 10.4 9.6 0.66 1.10(0.73-1.64) df=2  
3 A C G G 5 4.2 0.51 1.21(0.68-2.15)    P=0.72 
4 G C G G 0.2 - - -  
5 G C G A 0.2 - - -  
6 G G G G - 0.2 - -  
7 A C C G 0.6 - - -  
8 A G C A 0.1 - - -  
9 A G G A 0.6 1.2 - -   
The estimated haplotype frequency of patients and controls was compared by using SHEsis software 
platform. 
 
3.3.  Impact of polymorphisms on pain perception 
To explore the association between selected SNPs and 13 QST parameters, 
Kruskal-Wallis test and Jonckheere-Terpstra test were performed to test for 
subgroups. The results are presented from Table 7 to Table 12. There was a clear 
correlation between TRPA1 polymorphisms 710G>A and MPT and MPS,  
as well as between 3228A>G and MPT and MPS of test side in central pain subgroup 
 - 27 - 
(710G>A, P=0.021 and P=0.021, respectively, Kruskal wallis test; 3228A>G, P=0.007 
and P=0.007, respectively, Kruskal wallis test, as shown in 
Table 6).The homozygote A-allele carrier in 710G>A showed less sensitivity to pain 
perception than GA allele at locus 710 in mechanical pain sensitivity (MPS) 
measurement (P=0.028 Mann-Whitney U test) (Figure 6a). Moreover, in machincal 
pain thresholds (MPT) measurement, the heterozygote 710GA seems less sensitive 
to pain perception than homozygote G allele carrier (Figure 6b). The MPT z-score of 
test side in TRPA1 polymorphism A3228G indicated that the homozygote 3228G 
carriers were more likely to be loss of sensitivity than homozygote 3228A and 
heterozygote GA carriers (P=0.032 and P=0.048, respectively (Figure 6C). Similarly, 
the comparison of MPS z-score of test side apparently showed that the TRPA1 
homozygote 3228G carriers were also more  insensitive to the pain perception than 
homozygote 3228A but not heterozygote carriers( P=0.03 Mann-Whitney U test ). 
   In CRPS patients, statistically significant associations were found between the 
TRPV1 polymorphism 1911A>G and MPS on test side (P=0.003). The homozygote 
1911G carrier showed less sensitive to pain perception than homozygote 1911A 
(P=0.011) (Figure 6e). Compared the cold detection threshold (CDT) and thermal 
sensitivity limen (TSL) with each SNP, there was also markedly significant difference 
in TRPA1 polymorphisms 1911A>G (P=0.03 and P=0.046, respectively, Kruskal 
wallis test) on control side, the further comparison depending on the genotypes 
indicating patients carrying homozygote 3228G was more sensitive to cold stimui than 
heterozygote 3228AG and homozygote 3228A carriers (P=0.026 and P= 0.024, 
respectively, Mann-Whitney U test) (Figure 6g). 
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Tab. 7: Association between pain perception and SNPs from 3 TRP genes in 17 
central pain patients. 
 
  CDT WDT TSL CPT HPT MDT 
  T C T C T C T C T C T C 
Genes SNPs             
TRPV1 G1103C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A1911G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
TRPM8  C2235T a a a a a a a a a a a a 
 G1296A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 G780C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A787T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 G790C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A792G a a a a a a a a a a a a 
TRPA1 C182T a a a a a a a a a a a a 
 G710A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A3228G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
  MPT MPS WUR VDT PPT   
  T C T C T C T C T C   
Genes SNPs             
TRPV1 G1103C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A1911G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
TRPM8  C2235T a a a a a a a a a a   
 G1296A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 G780C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A787T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 G790C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A792G a a a a a a a a a a   
TRPA1 C182T a a a a a a a a a a   
 
G710A 0.021 0.043  0.021  n.s    n.s 
(K-W) (K-W) (K-W) 
n.s n.s n.s n.s n.s 
  
 
 0.004       0.004 
(J-T)         (J-T) 
      
  
 
A3228G 0.007  n.s  0.007  n.s   n.s 
(K-W).       (K-W) 
n.s n.s n.s n.s n.s   
 
 0.001       0.002 
(J-T)        (J-T) 
      
    
K: Kruskal-Wallis test; J: Jonckheere-Terpstra test; T: test side; C: control side; n.s : no significance 
a .The Kruskal Wallis Test was conducted to compare 13 items of QST parameters with selected SNPs from 
TRP gene. b: The Kruskal wallis test cannot be performed in “a” row due to lack of valid cases.  
In this subgroup, there is a significant correlation between TRPA1 polymorphisms 710G>A and MPT and 
MPS, the significant correlation between TRPA1 A3228G and MPT and MPS. Furthermore, the 
Jonckheere-Terpstra test on test side suggests there is a z-score trend dependent on genotypes. 
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Tab. 8: Association between pain perception and SNPs from 3 TRP genes in 56 
CRPS patients 
 
    CDT WDT TSL CPT HPT MDT 
    T C T C T C T C T C T C 
Genes SNPs             
TRPV1   G1103C 
 
n.s 0.03(K) n.s 
0.045(J) 
n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A1911G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
TRPM8   C2235T a a a a a a a a a a a a 
 G1296A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 G780C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A787T a a a a a a a a a a a a 
 G790C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A792G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
TRPA1 C182T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 
G710A n.s 0.035(K)n.s 
0.014(J)  
n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 
A3228G n.s 0.03(k)  n.s  
0.022(J) 
n.s n.s 0.03(K)  n.s 
0.022(J) 
n.s n.s 0.016(K) n.s   n.s 
 
    MPT MPS WUR VDT PPT   
    T C T C T C T C T C   
Genes SNPs             
TRPV1 
G1103
C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 
A1911G n.s n.s 0.003(K) n.s 
0.001(J) 
n.s n.s n.s n.s n.s n.s 
  
TRPM8  C2235T a a a a a a a a a a   
 G1296A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 G780C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A787T a a a a a a a a a a   
 G790C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A792G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
TRPA1 C182T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 G710A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 
A3228G n.s n.s n.s n.s 0.019(K) n.s 
 
n.s n.s n.s n.s 
  
K: Kruskal-Wallis test; J: Jonckheere-Terpstra test; T: test side; C: control side; n.s : no significance 
 
In CRPS patients, there is a significant correlation was found between CPT of control side and TRPV1 
G1103C, TRPA1 G710A and A3228G, there are also statistically significant correlation between TSL of 
control side and TRPA1 A3228G, MPS of test side and TRPV1A1911G. Furthermore, Jonckheere-Terpstra 
test shows significant trends in data mentioned above. However, the significant trends were not found 
between HPT of control side and TRPA1 A3228G, WUR of test side and TRPA1 A3228G.  
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Table 9: Association between pain perception and SNPs from 3 TRP genes in 27 peripheral 
nerve injury patients 
 
    CDT WDT TSL CPT HPT MDT 
    T C T C T C T C T C T C 
Genes SNPs             
TRPV1 G1103C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A1911G n.s n.s n.s 0.008(k) n.s n.s 0.024(k) n.s n.s n.s n.s n.s 
TRPM8  C2235T a a a a a a a a a a a a 
 
G1296A n.s n.s n.s n.s n.s n.s 0.035(k) n.s 
0.033(J) 
n.s n.s n.s n.s 
 
G780C n.s n.s n.s n.s n.s n.s 0.033(k) n.s 
0.033(J) 
n.s n.s n.s n.s 
 A787T a a a a a a a a a a a a 
 G790C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A792G a a a a a a a a a a a a 
TRPA1 
C182T 0.04(k)0.024(k) n.s 
0.004(J)0.024(J) 
n.s n.s n.s 0.005(k) n.s 
0.005(J) 
n.s n.s n.s n.s 
 G710A    n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A3228G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
    MPT MPS WUR VDT PPT   
    T C T C T C T C T C   
Genes SNPs             
TRPV1 G1103C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A1911G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
TRPM8  C2235T a a a a a a a a a a   
 G1296A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 G780C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A787T a a a a a a a a a a   
 G790C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A792G a a a a a a a a a a   
TRPA1 
C182T 0.027(k) n.s 
0.027(J) n.s n.s n.s n.s n.s n.s n.s n.s   
 G710A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A3228G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
K: Kruskal-Wallis test; J: Jonckheere-Terpstra test; T: test side; C: control side; n.s : no significance 
 
In peripheral nerve injury patients, z-score of CPT of test side is significantly associated with TRPM8 
G1296A, G780C and TRPA1 C182T. There is significant correlation between CDT of test side and TRPA1 
C182T. Similarly, the z-score of MPT of test side is significantly associated with TRPA1 C182T. Morover, 
Jonckheere-Terpstra test shows significant trends in data mentioned above , but there is no significant 
trends comparing TRPV1A1911G with WDT and CPT. 
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Table 10: Association between pain perception and SNPs from 3 TRP genes in 27 
PHN patients 
    CDT WDT TSL CPT HPT MDT 
    T C T C T C T C T C T C 
Genes SNPs             
TRPV1 G1103C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A1911G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
TRPM8  C2235T a a a a a a a a a a a a 
 G1296A n.s n.s n.s n.s n.s n.s 0.024(k) n.s n.s n.s n.s n.s 
 
G780C n.s n.s n.s n.s n.s n.s 0.021(k) n.s 
0.021(J) 
n.s n.s n.s n.s 
 A787T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 G790C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 
A792G n.s n.s n.s n.s n.s n.s 0.021(k)n.s 
0.021(J) 
n.s 
 
n.s n.s n.s 
TRPA1 C182T n.s n.s n.s n.s n.s n.s n.s  n.s n.s n.s n.s n.s 
 
G710A n.s n.s n.s n.s n.s n.s 0.044(k) n.s 
0.044(J)  
n.s 
 
n.s 0.049(k) n.s 
0.049(J) 
 A3228G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
    MPT MPS WUR VDT PPT   
    T C T C T C T C T C   
Genes SNPs             
TRPV1 G1103C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A1911G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
TRPM8  C2235T a a a a a a a a a a   
 G1296A n.s n.s n.s n.s n.s n.s 0.037(k) n.s n.s n.s   
 
G780C n.s n.s n.s n.s n.s n.s 0.029(k) n.s 
0.029 (J) 
n.s n.s 
  
 A787T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 G790C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 
A792G n.s n.s n.s n.s n.s n.s 0.029(k) n.s 
0.029(J) 
n.s n.s 
  
TRPA1 C182T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 
G710A 0.031(k) n.s 
0.031(J) 
n.s n.s n.s n.s n.s n.s n.s n.s  
 
 
A3228G 0.022(k) n.s 
0.022(J) 
n.s n.s n.s n.s n.s n.s n.s n.s 
  
K: Kruskal-Wallis test; J: Jonckheere-Terpstra test; T: test side; C: control side; n.s : no significance 
In post-herpetic neuralgia patients, z-score of CPT of test side is significantly associated with TRPM8 
G1296A, G780C and TRPA1 G710A. A significant correlation was found between VDT of test side and 
TRPM8 G780C as well as A792G. Meanwhile, the z-score of MPT of test side is significantly associated 
with TRPA1 G710A as well as A3228G. Additinally, there is a significant correlation between MDT of test 
side and TRPA1 G710A. Morover, Jonckheere-Terpstra test shows significant trends in data mentioned 
above. The significant trend was not observed between CPT of test side and TRPM8 G1296A. 
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Table 11: Association between pain perception and SNPs from 3 TRP genes in 71 
polyneuropathy patients 
 
  CDT WDT TSL CPT HPT MDT 
  T C T C T C T C T C T C 
Genes SNPs             
TRPV1 G1103C n.s n.s n.s n.s n.s 0.037(k) n.s n.s n.s n.s 0.029(k) n.s 
 A1911G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
TRPM8  C2235T a a a a a a a a a a a a 
 G1296A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 G780C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A787T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 G790C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A792G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
TRPA1 C182T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 G710A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A3228G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
  MPT MPS WUR VDT PPT   
  T C T C T C T C T C   
Genes SNPs             
TRPV1 G1103C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A1911G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
TRPM8  C2235T a a a a a a a a a a   
 G1296A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 
G780C n.s n.s n.s 0.041(k) n.s 
0.041(J) 
n.s n.s n.s n.s n.s 
  
 A787T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 G790C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 
A792G n.s n.s n.s 0.045(k) n.s 
0.045(J) 
n.s n.s n.s n.s n.s 
  
TRPA1 
C182T n.s n.s n.s n.s 0.045(k)0.045(k) n.s 
0.045(J)0.045(J)  
n.s n.s n.s 
  
 G710A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A3228G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
K: Kruskal-Wallis test; J: Jonckheere-Terpstra test; T: test side; C: control side; n.s : no significance 
 
In polyneuropathy patients, the MPS of test side is significantly associated with TRPM8 G780C as well as 
A792G. A significant correlation was found between WUR of both sides and TRPA1 G780C.Furthermore, 
further Jonckheere-Terpstra test suggests significant trends in data mentioned above. There is significant 
association without trend between TRPV1 G1103C and TSL of control side as well as MDT of test side 
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Tab. 12: Association between pain perception and SNPs from 3 TRP genes in 30 
trigeminal patients 
 
    CDT WDT TSL CPT HPT MDT 
    T C T C T C T C T C T C 
Genes SNPs             
TRPV1 G1103C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A1911G 0.035(k) n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
TRPM8  C2235T a a a a a a a a a a a a 
 G1296A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 G780C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A787T a a a a a a a a a a a a 
 
G790C n.s n.s n.s n.s 0.024(k) n.s 
0.024(J) 
n.s n.s n.s n.s n.s n.s 
 A792G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
TRPA1 C182T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 G710A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
 A3228G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
    MPT MPS WUR VDT PPT   
    T C T C T C T C T C   
Genes SNPs             
TRPV1 G1103C n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A1911G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
TRPM8  C2235T a a a a a a a a a a   
 
G1296A n.s n.s n.s n.s n.s n.s 0.041(k) n.s 
0.041(J) 
n.s n.s 
  
 
G780C n.s n.s n.s n.s n.s n.s 0.04(k) n.s 
0.04(J) 
n.s n.s 
  
 A787T a a a a a a a a a a   
 
G790C n.s n.s 0.008(k)0.012(k)n.s 
0.008(J)0.012(J) 
n.s n.s n.s n.s n.s 
  
 
A792G n.s n.s n.s n.s n.s n.s 0.04(k) n.s 
0.04(J) 
n.s n.s 
  
TRPA1 C182T n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 G710A n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
 A3228G n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s   
K-W:Kruskal-Wallis test;J-T:Jonckheere-Terpstra test; T: test side; C: control side; n.s : no significance 
 
In trigeminal patients, the TSL of test side is significantly associated with TRPM8 G790C. A significant 
correlation was found between MPS of both sides and TRPM8 G790C. Similarly, there is significant 
association between the VDT of test side and TRPM8 G1296A, G780C as well as A792G. Furthermore, 
further Jonckheere-Terpstra test suggests significant trends in data mentioned above. There is significant 
association but trend between TRPV1 A1911G and CDT of test side.       
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Considering the TSL, the homozygote G-allele carriers in TRPA1 SNP 3288A>G 
seems also less tolerance to thermal stimuli than homozygote carriers 3288 A 
(P=0.045) (Figure 6h). However, there was no significant influence on pain perception 
dependent on genotypes in the other SNPs compared with QST parameters. 
 
 
  
 
 
 
 
 
 
(a)  
(b) 
Figure 6a: Comparison of 
MPS of test side depending on 
TRPA1 G710A genotypes in 
central pain patients  
 
Figure 6b: Comparison of 
MPT of test side depending on 
TRPA1 G710A genotypes in 
central pain patients  
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(c) 
(d) 
(e) 
Figure 6c: Comparison of 
MPT of test side depending on 
TRPA1 A3228G genotypes in 
central pain patients  
Figure 6d: Comparison of 
MPS of test side depending on 
TRPA1 A3228G genotypes in 
central pain patients  
Figure 6e: Comparison of 
MPS of test side depending on 
TRPV1 A1911G genotypes in 
complex regional pain 
symdrom (CRPS) patients  
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Figure 6: Comparison of z-score of QST parameters in some associated SNPs 
dependent on genotypes. (P-values calculated by Mann-Whitney U-test.)  
(f) 
(g) 
(h) 
Figure 6f: Comparison of CDT 
of control side depending on 
TRPV1 G1033C genotypes in 
centrol pain patients  
 
Figure 6g: Comparison of 
CDT of control side depending 
on TRPA1 A3228G genotypes 
in GRPS patients  
 
Figure 6h: Comparison of TSL 
of control side depending on 
TRPA1 A3228G genotypes in 
GRPS patients  
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4.  DISCUSSION  
 
4.1. The characteristics of neuropathic pain in the seven subgroups  
Neuropathic pain is a chronic pain syndrome that has been associated with drug-, 
disease-, or injury-induced damage or destruction of the sensory afferent fibers of the 
peripheral nervous system (PNS), and has a substantial impact on quality of life and 
mood [30]. Our clinical data, which include seven types of neuropathic pain, showed 
that sensory alternations diversified depending on these different diseases. For 
example, in central pain patient, post-herpetic neuralgia PHN as well as 
polyneuropathy patient, the pain patterns characterized by loss of sensory function 
are apparently distinct from the complex regional pain syndrome type (CRPS) patients, 
who often exhibited the pain pattern of gain of sensory of function like hyperalgesia. 
Our findings are consistent with the phenomenon in previously published literature, in 
which the type of pain could manifest not only with positive sensory phenomena, such 
as pain, dysesthesia, and different types of hyperalgesia, but also with negative 
sensory phenomena and negative and positive motor symptoms and signs [31, 32]. 
Among thirteen QST parameters applied, the z-score of cold detection threshold 
(CDT), mechanical detection threshold (MDT), thermal sensitivity limen (TSL), 
mechanical detection threshold (MDT) and vibration detection threshold (VDT) in 
central pain showed negative alterations in sensory function, suggesting that small 
and large sensory fiber like afferent C- or Aδ-fiber could be implicated as a 
consequence of long-duration pathological lesion. More interestingly, the VDT z-score 
of CRPS patients showed hyperalgesia to blunt pressure, a phenomenon of feeling 
vibration response to in-noxious stimuli. In contrast, the VDT z-score in peripheral 
nerve injury and polyneuropathy subgroups exhibited the loss of sensory function. 
Similarly, the MDT z-score of PHN and polyneuropathy patient indicated loss of 
function in mechanical stimuli sensitivity. It is reported that Aβ-fiber is represented by 
the VDT and MDT, May be lesions involving this type of afferent fiber probably result 
in the gain or loss of function of mechanical sensitivity. Since the ability of peripheral 
nervous system (PNS) to sense and perceive pain is an essential protective 
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mechanism that warns against threatened or ongoing tissue damage. Disruption of 
this protective mechanism may result in the development of chronic pain. On the other 
hand, the lower efficiency of endogenous pain modulation induced by alternation in 
CNS pain processing, which in part attenuate the pain inhabitation, probably play a 
crucial role in the origin of the neuropathic pain. In addition, several molecular 
mechanisms, such as abnormal release of neurotransmitter (e.g. norepinephrine, NE), 
increased neuronal hyperexcitability as well as unbalanced between excitatory (e.g. 
glutamate) and inhibitory (e.g gamma-aminobuytric acid, GABA) transmitter system, 
commonly lead to the dysfunction on pain signalling pathway, and creating a state of 
allodynia and hyperalgesia or hypoesthesia [33, 34].  
 
4.2  Neuropathic pain and single nucleotide polymorphism 
Due to the multifactorial aetiology of neuropathic pain, a variety of treatment 
algorithms were adopted by clinicians to alleviate the symptoms. But the overall 
successful rate for treatment seems low because of the universal individual variability 
and needs to be improved urgently. Meanwhile, this intriguing phenomenon draws lots 
of attention to explore the underlying mechanism for relevant genes or SNPs, which is 
recently suspected to play a crucial role in the variability of pain perception. Up to now, 
there have been few genetic studies on human suggesting that single nucleotide 
polymorphisms of specific genes could contribute significantly to basal pain sensitivity. 
For example, Single-nucleotide polymorphisms of the µ-opioid receptor gene like 
OPRM1 and the catechol-O-methyltransferase (COMT) gene were shown to be 
associated with pain ratings in response to standardized noxious stimuli and with 
pain-induced µ-opioid receptor binding in the CNS [22, 35, 36]. The polymorphism 
OPRM1A118G, however, leading to a lower affinity of ligands to the extracellular 
binding domain of the µ-opioid-receptor, seems more likely to be associated with the 
acute pain [37]. It is commonly reported that postoperative patients carrying 
homozygously 118G, exhibit a higher pain sensitivity and require higher opioids 
dosages than those being homozygous for 118A. Another common functional 
polymorphism 1947G>A in COMT gene cause substitution from valine to methionine 
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at amino acid position 158, which is suggested to increase pain sensitivity and to 
decrease opioid system activation in the brain [38]. Haplotypes including COMT 
Val158Met were recently identified and an association was suggested with 
experimental pain sensitivity and a chronic pain condition [22]. However, there are still 
controversial findings concerning this SNP in acute pain patients or in different 
ethnicities [15, 33].  
Recently, there is increasing evidence supporting that hypersensitivity and pain that 
occurs under various pathological conditions is often due to up-regulated expression 
and/or increased sensitivity of TRP channels. Several lines of evidence point to the 
involvement of members of the TRPV family in the aetiology of neuropathic pain 
[39,40], So far, considering the potentially functional role of polymorphism in TRP 
gene, only few information on humans has been explored regarding the association 
between pain perception and TRP genetic polymorphisms. Recently, a study led by 
Xu et al [41] suggested that TRPV1 Met315lle variant might lead to functional 
difference at the level of expression at the cell surface, on a HEK293 cells model. 
Furthermore, a body of previous literature focuses on racial differences in the pain 
perception response to painful stimuli [42]. For example, two clinical studies found 
that Asian patients may require less post-operative analgesia than European patients 
[43]. This phenomenon, however, has not been replicated in all reported studies [44].  
 
4.3  Genetic variability of TRPV1 and their influence on pain perception  
In this study, the genotype distribution of 11 selected TRP gene polymorphisms were 
examined in neuropathic pain patients and volunteers, trying to explore whether there 
has been a biologically relationship between these SNP and alterations of pain 
sensitivity. Among these markers, two common single nucleotide polymorphisms 
TRPV1 1103 C>G and 1911 A>G, also known as TRPV1 Met315Lle and LIe585Val, 
result in  substitution from methionine to isoleucine at codon 315 and isoleucine to 
valine at codon 585,repectively[22, 45]. They are 12.7 kb apart from each other in the 
genomic sequence. We found the allelic frequency for the 1911 A>G polymorphism 
was statistically significant higher in patients compared with controls (P=0.04). The 
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overall G allelic frequency in patients was 36.8%, which was similar to those reported 
in the HapMap database (34.2%) and in the study led Kim et al (36.0%). More 
interestingly, the overall allelic frequency of the 1911A>G polymorphism in control 
group approaches 42.8%. Although the genotype frequency of 1911GG carriers in 
control group was 18.8%, slightly higher than the patient group (14.6%), there is no 
significant difference (P=0.14, χ2=3.86) between patient and control group. Our data 
still indicated that neuropathic pain patients were less likely to carry the TRPV1 
1911G allele at this position.   
Until now, conflicting findings over TRPV1 polymorphisms still exist. For the TRPV1 
1911A>G polymorphism, no different functional response to capsaicin, pH and 
temperature between the different alleles has been detected in whole-cell 
patch-clamp and calcium imaging experiments, suggesting that the substitution does 
not critically alter receptor structure or function, at least in vitro[46]. Conversely, Kim et 
al [47] observed that this polymorphism alters cold withdrawal times (CWT i.e, 
increased sensitivity to cold-induced pain). From several animal experiments, there 
was some evidence derived supporting that TRPV1 after long-term activation could 
exert a protective role in the development of mechanical hyperalgesia [48], even 
though the detailed mechanism was not finally clarified. Considering our control group 
with the higher allele frequency in TRPV1 1911A>G, the question remains open as to 
whether the carrier with G allele in neuropathic pain subject have a potentially 
protective role from aggravating into further stage. So, further study should be 
investigated to confirm this hypothesis.  
TRPV1 likely plays a major role in integrating nociceptive signals, particularly in the 
contexts of inflammatory and neuropathic pain [49, 50]. When comparing genotype 
data in patients with 13 of the PSQ parameters, a statistically significant correlation 
was found between mechanical pain sensitivity (MPS), cold detection threshold (CDT) 
and polymorphism TRPV1 1911A>G in CRPS patients (P=0.003 and 
P=0.03,respectively). Our results are not consistent with the previously published 
finding by Kim et al [22], in which they failed to find any significant association 
between these two polymorphisms in TRPV1 and cold/heat pain sensitivity in 
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American female subjects of European descent. In their study, the different 
experimental environment used, which includes taking healthy subjects, different 
methods of pain measurement, pain parameters selected as well as the racial 
difference may explain this inconsistency. In our study, MPS was designed to detect 
an typical phenomenon, termed pinprick hypoesthesia, which was often complicated 
with the neuropathic pain and was believed to be consistent with a large fiber sensory 
deafferentation like afferent Aδ-fiber, and the presence of abnormal cold pain 
threshold (CDT) in GRPS subgroup also indicates a disturbance of Aδ-cold sensory 
function, which might indirectly reflect the damage extent on the afferent pain 
signalling pathway, and evaluate the influence on the pain sensitivity. However, the 
relative contribution of C- and Aδ-fiber nociceptors to cold and pressure pain 
threshold is less clear [28, 51]. Based on our results, we could conclude that TRPV1 
1103G>C and 1911A>G was closely associated with the pain perception in certain 
type of neuopathic pain, especially for thermal and mechanical sensitivity. Many 
evidences suggested TRPV1 plays an important role in chemical and thermal 
hyperalgesia in a model of diabetic neuropathy [52]. Its role may be associated with 
decreased cell-specifically TRPV1 protein expression in C-fibers paralleled by an 
increase in A-fibers, leading to an increase in its function. Furthermore, a possible 
“cooperation” between TRPA1 and TRPV1 channels has also been reported in recent 
vitro study, in which the canabinoid agonist WIN 55,212-2 dephosphorylates, 
therefore desensitizing TRPV1 in trigeminal sensory neurons via the activation of 
TRPA1.   
With regard to the comparison of the MPS z-value with TRPV1 polymorphisms, the 
results of test side clearly showed that homozygote 1911G carriers are more likely to 
exhibit the loss of sensory function than homozygote A1911 carriers. Similarly, the 
comparison of mechanical pain threshod (MPT) z-score on control side indicated that 
subjects carrying TRPV1 1911GA are less sensitive to the cold stimuli than those who 
carrying homozygote 1911A, representing loss of sensory function. Impaired pain 
sensation might result from distorted TRPV1 regulation in the peripheral nervous 
system, there is quite a little vivo data recently supported that TRPV1 protein 
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expression could be enhanced by IGF-I via PI(3)K signal pathway [53]. Moreover, as 
a target of the cAMP/PKA signal pathway, the effect of TRPV1 under tissue 
inflammation or nerve injury might also be influenced by alteration of PKA-mediated 
phosphorylation [54].So, it can also be speculated that the substitution of amino acid 
caused by SNP TRPV1 1103G>C and 1911A>G probably alters biological function on 
afferent fiber or primary sensory neuron by altering secondary structure of mRNA or 
TRPV1 protein expression, leading to individual differences of pain sensitivity. 
 
4.4  Association of TRPM8 genotypes with neuropathic pain  
We found no difference in the genotype or allelic frequencies for these five SNPs in 
TRPM8 gene between patients or controls, indicating that there was no evidence for 
an association of risk of developing neuropathic pain. The genotype or allelic 
frequencies in our patients and controls were also similar to those reported in HapMap 
database. Interestingly, some SNPs in the TRPM8 gene, namely 2235C>T (Thr762Tle), 
780G>C (Arg247Thr), 787A>T (synonymous), 790G>C (synonymous) and 792A>G 
(Tyr251Cys), could not be found in our patients. Among these SNPs, two out of them 
do not seem to be polymorphic in our volunteers. From the HapMap, we found that the 
minor allele frequency of 780 A>C and 790G>C in Asia population but not in 
European population was always polymorphic, indicating the existence of an ethnic 
difference in these two SNPs. TRPM8 is a non-selective, outwardly rectifying channel 
that can be activated by cold (8-28 °C) [55], Up to date, there is increasing evidence 
that mutation in coding regions could contribute to the function of the TRPM8 channel. 
Dragoni et al [56] have identified two potential N-glycosylation sites in TRPM8 
(Asn-821 and Asn-934) in rats, and observed the decreased efficiency of synthesis of 
mature, glycosylated TRPM8 as a result of mutation. It is widely accepted now that 
TRPM8 may play a major role in certain types of cold-induced pain [57]. 
In this study, comparing five TRPM8 SNPs with 13 QST parameters, no significant 
association was found dependent on the genotypes mostly because of no valid case 
in each subgroup. Also Kim et al failed to find any association between TRPM8 
variant and cold as well as heat pain sensitivity in their healthy European Americans. 
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However, considering the relatively higher range of threshold temperature to TRPM8 
(8-28 °C), it is likely that the TRPM8 receptor was not activated by the painful cold 
temperature they used (2-4 °C) [22]. Nevertheless, it still raises the intriguing 
possibility that genetic polymorphisms, such as those investigated here, may account 
for or contribute to a racial difference in pain threshold or tolerance. In addition, animal 
experiments showed that mutation in TRPM8 gene could contribute to the function of 
this TRPM8 channel [57]. It is possible, therefore, that one SNP may be in linkage with 
another functional SNP in the TRPM8 gene, inducing an impact on behavioural 
phenotype such as pain perception difference through an epigenetic mechanism 
related to this nucleotide substitution.  
Duan et al [58] showed that synonymous SNPs within haplotypes may have functional 
consequences drastically different from those of each isolated variant. This effect was 
attributed to alterations in the secondary structure of mRNA, which result in weakened 
mRNA stability or protein translation. Furthermore, it has been well documented that 
TRPM8 is mostly present in small diameter sensory neurons, and all 
TRPM8-expressing neurons also expressed receptor tyrosine kinases (TrkA), which is 
a NGF receptor [59]. For those TRPM8 SNPs involving amino acid substitution, such 
as 1296G>A and 780G>C, the question remains open whether these polymorphisms 
might alter the expression of TRPM-8 receptor through the nerve growth factor (NGF) 
pathway. 
 
4.5 Genetic variability of TRPA1 and association to pain perception  
The genotype and allele distribution of three TRPA1 SNPs investigated was identical 
in our patients and controls, and there was no evidence for an association to risk of 
neuropathic pain. All the genotype and allelic frequencies were similar to those 
reported in Hapmap database in European population supporting the generalizability 
of the findings. Regardless of TRPA1 182C>T, the minor allelic and genotype 
frequency of TRPA1 710G>A and 3228A>G reported in HapMap database showed 
significant difference among ethnic groups, which should also be considered in 
association studies with SNPs and phenotypes. 
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Considering the results of pain perception in central pain subgroup, we found that 
TRPA1 SNPs 710G>A and 3228A>G were significantly associated with MPT and 
MPS on affected side of the patient. Compared mechanical pain threshold (MPT) 
z-score depending on the genotype in SNPs A3228G, central pain patients carrying 
homozygously the 3288G allele, tended to be insensitive to pain perception than  
homozygote 3288A carriers (P=0.032 in MPT and P=0.03 in MPS, respectively, 
Mann-Whitney U-test) and heterozygote GA carriers (P=0.048 in MPT). A similar 
result was found for TRPA1 710G>A, but possibly due to the low allelic frequency - the 
difference was only significant in heterozygote GA carriers (P=0.013 in MPT and 
P=0.013 in MPS, respectively, Mann-Whitney U-test). The decreased mechanical 
pain thresholds or pain sensitivity in central pain patients could be linked to the 
disturbance of afferent Aδ-fiber. Furthermore, the MPT or MPS parameter could be 
used to detect the mechanical pain stimuli and to determine whether patients with 
pain processing abnormalities (i.e. neuropathic pain) show exaggerated temporal 
summation of second pain intensity [49]. The mechanism involving 
N-methyl-D-aspartate (NMDA) receptor within the dorsal horn is thought to be 
responsible for temporal summation of pain [60]. This finding was partially in 
agreement with the receptor function in previously published literature [61], in which 
the TRPA1 was believed to be a sensor for mechanical stimuli. Under neuropathic 
pain status, alterations in neuronal function, chemistry, and structure, which often 
occurred secondary to nerve injury, might result in abnormal expression of TRPA1 
receptor, leading to loss of sensory function. It is still unclear which mechanism gets 
involved in the decreased afferent fibers function in the homozygote 710A. The amino 
acid substitution caused by this polymorphism from histidine to arginine at position 
1018 could be one possible reason to contribute to this different sensitivity. In addition, 
one interesting property of TRPA1 channels, which inactivate in hyperpolarized cells 
but remain open in depolarized cells, also provides a mechanism for the lack for 
desensitization, coincidence detection, and allodynia [63]. However, whether the 
amino acid change induced by polymorphism alters these depolarized cells leading to 
influence on iron influx still need to be considered in future studies. 
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The comparison data of QST parameters like thermal sensitivity limen (TSL) and cold 
detection threshold (CDT) on the non-affected control side of the patient for TRPA1 
A3228G also indicated that homozygote 3288G carriers of CRPS patients were more 
sensitive to pain perception than homozygote A3288 (in CDT) and heterozygote AG 
carriers (both CDT and TSL). A great amount of evidence supporting that TRPA1 has 
also been linked to cold hyperalgesia behind neuropathic pain [38, 64]. Inflammation 
and nerve injury increase the expression of TRPA1 in DRG neurons. Furthermore, the 
co-expression of TRPA1 and TRPV1 and the flexibility of the TRP family channels 
raise the possibility that TRPA1 channel might interact to influence the properties of 
one another [19, 64]. Animal experiments showed that an NGF-induced TRPA1 
increase in sensory neurons via p38 activation is necessary for cold hyperalgesia [38, 
65]. Other studies further demonstrated that mice following trpa1 gene knock out or 
trpa1 antagonist exhibited behavioural changes in response to the pain stimuli, which 
illustrated the important role of TRPA1 in pain perception. 
 
4.6 Limitation of our study 
There are still some limitations in the study. Firstly, the volunteers were not 
investigated by the QST test panel, which consequently failed to powerfully evaluate 
the variability in pain perception among healthy subjects. Secondly, in the study, 
patients in subgroups apparently showed different pain pattern dependent on the 
aetiology of the neuropathic pain. Therefore we necessarily further compared z-score 
with associated SNPs for each subgroup based on the genotype, which probably 
increases the ability to study phenotype-genotype association. But owing to no valid 
cases in some of subgroups, larger sample are necessary in order to get stronger 
statistic power. Finally, functional test based on the vivo or vitro study should be 
performed to directly measure the effect of these SNPs as to confirm the association 
and to provide a stronger rationale for the relationship with pain sensitivity. Our 
association analyses have identified several loci associated with thermal and 
mechanical pain sensitivity, but their functional importance has yet to be confirmed. 
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4.7 Conclusion  
In conclusion, our results have a considerable clinical significance and represent the 
first study of this kind which demonstrated an association between several genetic 
polymorphisms like TRPV1 1103C>G, 1911A>G, 710G>A as well as 3228A>G and 
pain sensitivity. These SNPs produce different influences on pain perception 
dependent on the genotype in patients on the condition of neuropathic pain. As far as 
complex regional pain syndrome (CRPS) patients are concerned, the subjects 
carrying the minor homozygote 3228G exhibited more sensitivity in response to 
thermal pain stimuli, than those with wild-type homozygote carriers. In contrast, 
homozygote 1103C, 1911G carriers were more insensitive to mechanical and thermal 
stimuli than homozygote G1103, A1911carriers, which were consistent with the 
influence of homozygote 3288G carriers on WPT and WPS in central pain subgroup. 
These polymorphisms exert major effects maybe by influencing the level of 
expression of the gene product, dependent of its function. Finally, these 
polymorphisms alone or interaction between SNPs may alter transcription, mRNA 
stability, or the protein half-life, leading to the association with a certain clinical status. 
For those polymorphisms without involving amino acid substitution, the observed 
relationship between associated SNPs and pain perception could be caused by other 
functional polymorphisms in the neighbouring genes that posses high LDs with tested 
SNPs. Although there was no evidence of an association between genotypes and the 
risk of being neuropathic pain, for the TRPV1 1911A>G, the relative lower proportion 
in homozygote 1911G in patient compared to healthy volunteers possibly indicated 
that  subjects likely carrying the common G allele at this position have a potentially 
protective role, preventing the aggravation in the further stages.  
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5.  SUMMARY 
Neuropathic pain is a chronic pain syndrome that has been associated with drug-, 
disease-, or injury-induced damage or destruction of the sensory afferent fibers of the 
peripheral nervous system (PNS). The type of pain could be manifested not only with 
positive sensory phenomena, such as pain, dysesthesia, and different types of 
hyperalgesia, but also with negative sensory phenomena and negative and positive 
motor symptoms and signs. The pharmacological treatment of the symptoms of 
painful neuropathy, however, is still considered to be difficult. Nowadays, much 
attention is focused on the genetic polymorphisms, some of the single nucleotide 
polymorphisms can be speculated to be associated with the pain sensitivity as a result 
of amino acid substitution in crucial position. But the detailed knowledge of individual 
variability on pain perception under neuropathic pain is still poorly understood. 
Candidate gene studies on the basis of biological hypothesis have been a practical 
approach to identify relevant genetic variation in complex traits. There is growing 
evidence showed that single nucleotide polymorphisms in related genes, including 
TRPV1, TRPA1 and TRPM8, may influence pain sensitivity in animal model of 
neuropathic pain. 
In our study, we selected 2 of the SNPs fromTRPV1, 3 of the SNPs from TRPA1 and 
6 SNPs from TRPM8 to examine the effect of these variations on clinical neuropathic 
pain responses, to investigate the contribution of genetic factors on pain sensitivity in 
humans. There were a total of 296 Germany patients and 253 healthy volunteers 
recruited in our study for investigation. Owing to the failed collection of clinical data in 
some cases, finally only 237 patients were enrolled to carry out the association 
analysis. The results show that patients exhibited markedly gain of sensory function 
along with the application of cold detection (CDT), thermal sensitivity limen (TSL) on 
control side. The hypoesthesia, however, was occurred on test side when patients 
were giving mechanical pain threshold (MPT) and mechanical pain sensitivity (MPS) 
measure. The comparison of seven subgroups between test and control side showed 
that there are different pain patterns based on the subgroups. Besides the trigeminal 
pain and other neuropathy patients, the five other subgroups exhibiting either the loss 
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of sensory function in CDT, WDT, TSL and VDT on central pain, or the gain of 
sensory function in pressure pain threshold (PPT) in CPRS patient. Referring to the 
genotype and allele frequencies on patients and controls, there are no significant 
differences between the two groups, except the TRPV1 polymorphism A1911G.  
With regard to the association between SNPs and 13 QST parameters, there were 
some significant correlations related to TRPV1 polymorphisms 1103 C>G and 
1911A>G, as well as to TRPA1 polymorphism 710G>A and 3228A>G with several 
QST parameters in two neuropathic pain subgroups. The CRPS patients carrying 
homozygote G in TRPA1 3228A>G were more sensitive to pain perception than those 
patients carrying the heterozygote genotype in the TSL and CDT test, conversely, in 
some subgroups homozygote TRPV1 1911G carriers were more likely to be 
insensitive to sensory pain than homozygote 1911A carriers; Similarly, further 
comparison of the data indicated that patients carrying homozygote TRPA1 710A or 
3228G were less sensitive to pain perception than heterozygote and homozygote 
G710 or 3228A carriers. 
The results suggest that at least some of these genetic polymorphisms may exert 
major effects on pain perception possibly by influencing the level of expression of the 
gene product, depending on its function. Finally, polymorphisms alone or interaction 
between SNPs may alter transcription, mRNA stability, or the protein half-life, leading 
to a specific clinical status. For those polymorphisms which do not involve amino acid 
substitution, the observed association with pain perception could be caused by other 
functional polymorphisms in the neighbouring genes that posses high LDs with tested 
SNPs. 
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